Topics:
Gynecologic Cancers • NCI-CCC Tumor Board Question • University of Utah • NCI-CCC Gynecologic Tumor Board Question
Do you consider an ovarian cancer patient who progresses on PARP inhibitor, either for treatment or maintenance, to be platinum resistant regardless of time since last platinum based chemotherapy?
Does the exact time since last platinum-based chemotherapy change your answer?
Answer from: at Academic Institution
I would not necessarily. The time since the last platinum is what would drive my answer. It may pan out in fact that the patient is no longer platinum sensitive, but I would not make that determination based on an assumption that progression on PARP = platinum resistance. Although we do say that pla...
Sign in or Register to read more